Adding Abiraterone to ADT May Decrease Resource Utilization in Castration-Naïve Prostate Cancer

Web Exclusives - Prostate Cancer
Wayne Kuznar

The addition of abiraterone acetate (Zytiga) to androgen-­deprivation therapy (ADT) did not increase medical resource utilization in patients with metastatic castration-naïve prostate cancer who participated in the multinational LATITUDE clinical trial.

The use of some resources, such as overnight hospitalization and imaging, declined in patients who were randomized to abiraterone plus ADT compared with those who received placebo plus ADT, said Tracy Li, PhD, Director of Global Market Access and Health Economics, Janssen, who presented the results at the 2018 Genitourinary Cancers Symposium.

The current treatment landscape for patients with castration-naïve prostate cancer is dynamic, although ADT remains a cornerstone therapy, Dr Li said. In the LATITUDE study, abiraterone added to ADT significantly improved overall survival and reduced disease progression compared with placebo plus ADT.

“To fully understand the economic consequences of adopting abir­aterone plus ADT for use in metastatic castration-naïve prostate cancer, an understanding of the medical resource use implications associated with treatment is required,” she said.

Head-to-Head Comparison

The objective of the current study was to compare event-driven medical resource utilization among the 1199 patients enrolled in LATITUDE. Specifically, medical resources other than those mandated by the study protocol were assessed from the first to the last dose of the study medication.

“We wanted to find out what it meant to the healthcare system when you have an effective treatment for a disease, and you improve the clinical aspects and slow down disease progression,” Dr Li said.

“Improving overall survival and radiographic progression-free survival, slowing down disease progression, and delaying the use of chemotherapy meant a decrease in overnight hospitalization, use of radiotherapy and surgery, and the need for imaging, with trends toward fewer visits to oncologists and urologists,” she added.

The proportion of patients with non–protocol-mandated medical resource utilization was 78% for hospitalizations, 81% for imaging, 82% for general practitioner visits, 87% for specialist visits, and 97% for radiotherapy.

The rates of hospitalization in the 2 study arms were 52.71 per 100 person-years in the abiraterone plus ADT arm compared with 69.47 per 100 person-years in the placebo plus ADT arm, amounting to a 24% reduction with the addition of abir­aterone to ADT.

The most common reasons for hospitalization were bladder or urethral symptoms (9%), limb fractures or dislocations (6%), spinal cord or nerve root disorders (5%), urinary tract infections (5%), lower respiratory tract or lung infections (4%), febrile disorders (4%), central nervous system hemorrhage or cerebrovascular accident (4%), musculoskeletal or connective tissue pain and discomfort (4%), and bronchospasm or obstruction (4%).

However, the use of imaging outside that mandated by protocol was significantly lower in the abiraterone arm compared with the placebo arm (rate ratio, 0.64; 95% confidence interval [CI], 0.49-0.84), and the use of radiotherapy was significantly lower in the abiraterone arm than in the placebo arm (rate ratio, 0.50; 95% CI, 0.25-1.00).

The rates for specialist visits, surgery, emergency department visits, and general practitioner visits were not significantly different between the 2 arms. The rate of visits to a general practitioner trended toward an increase in the abiraterone arm.

“Visits to the GP [general practitioner] are a mixed bag, because those visits can be for a variety of reasons beyond prostate cancer,” Dr Li observed. “They may not be related to treatment.”

Because LATITUDE was a multinational study, resource utilization rates might have varied by region or country, because of different standards of care for patients, the researchers noted.

Related Items
Enzalutamide or Apalutamide Added to ADT Are 2 New Options for Hormone-Sensitive Prostate Cancer
Phoebe Starr
Web Exclusives published on August 6, 2019 in Prostate Cancer
Darolutamide, New Androgen Receptor Inhibitor, Extends Metastasis-Free Survival in High-Risk Prostate Cancer
Phoebe Starr
Web Exclusives published on June 3, 2019 in Prostate Cancer
Paradigm Shift: Radiation a New Standard in Prostate Cancer with Low Metastatic Burden
Web Exclusives published on January 29, 2019 in Prostate Cancer
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
Web Exclusives published on December 4, 2018 in Prostate Cancer
Updated NCCN Prostate Cancer Guideline Emphasizes Risk Stratification
Wayne Kuznar
Web Exclusives published on September 28, 2018 in Prostate Cancer
Apalutamide and Enzalutamide Each Delays Prostate Cancer Metastasis by Approximately 2 Years
Web Exclusives published on May 31, 2018 in Prostate Cancer
Treat Your Patients as Customers by Meeting Their Expectations
Wayne Kuznar
Rheumatology Practice Management April 2018 Vol 6 No 2 published on April 16, 2018 in NORM Conference News
2017 HIPAA Updates and the Office for Civil Rights Audits
Wayne Kuznar
Rheumatology Practice Management October 2017 Vol 5 No 5 published on October 20, 2017 in NORM News
Abiraterone Is Game-Changer in the Frontline Treatment of Advanced Prostate Cancer
Wayne Kuznar
Web Exclusives published on July 21, 2017 in Prostate Cancer
Adding Antiandrogen Therapy to Radiation Improves Survival in Recurrent Prostate Cancer—A New Standard of Care?
Jessica Miller
Web Exclusives published on May 15, 2017 in Prostate Cancer
Last modified: March 7, 2019
  • American Health and Drug Benefits
  • Association for Value Based Cancer Care
  • Lynx CME
  • Oncology Practice Management
  • Rheumatology Practice Management